Lexaria Bioscience Corp. | Announces the Issuance of Options

Lexaria Bioscience Announces the Issuance of Options and Warrants

Kelowna, British Columbia – May 23, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that on May 22, 2019 it issued the following securities:

  1. Incentive Stock Options, pursuant to the Company’s registered equity compensation plan, as approved by its directors on May 1, 2019 (the “Options”). The Options are being issued to an independent consultant entitling the holder to purchase of up 48,000 common shares (“Shares”) at a price of US$0.96 per Share.  The Options are vested over a two year period with 16,000 Options being exercisable immediately, 16,000 Options being exercisable on February 24, 2020 and 16,000 Options being exercisable on February 24, 2021.  The Options will be subject to a four month hold period from the date of issue pursuant to Canadian Securities Exchange policy.
  2. Share Purchase Warrants (“Warrants”) to Oak Hill Financial Services Ltd. (“Oak Hill”), a consultant engaged by the Company to perform investor relations services, which Warrants entitle Oak Hill to purchase up to 100,000 Shares at a price of US$0.96 per Share. The Warrants are exercisable for a period of two (2) years, however only Warrants to purchase up to 50,000 Shares may be exercised until November 22, 2019.  The Warrants will be subject to a four month hold period from the date of issue pursuant to Canadian Securities Exchange policy.

The securities referred to herein have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.


About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs),nicotine and other molecules.



For regular updates, connect with Lexaria on Twitter https://twitter.com/lexariacorp

and on Facebook https://www.facebook.com/lexariabioscience/




Lexaria Bioscience Corp.

Alex Blanchard, Communications Manager

(250)765-6424 Ext 202


NetworkNewsWire (NNW)




This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&D is often unpredictable and unanticipated results could emerge from any study and have a material impact. There is no assurance that any planned corporate activity, scientific study, R&D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA).  TurboCBDTM, DehydraTECHTM technology and ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.


The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.